Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-26 02:01 UTC

BIOMED PULSE

Saturday, July 26, 2026 — Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15, making it the dominant global health emergency — and WHO's first-ever comprehensive filovirus treatment guidelines are now live alongside an enrolling treatment trial. Mood: urgent but scientifically mobilized; multiple fronts are active simultaneously. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, WHO confirmed 2,124 cases and 828 deaths from Bundibugyo virus disease (BVD) in DRC, with cross-border transmission ongoing in Uganda. [1]
  • WHO declared BVD a Public Health Emergency of International Concern on May 22, 2026; the IHR Emergency Committee noted the event does not yet meet the higher "pandemic emergency" threshold. [4]
  • Africa CDC and WHO jointly launched a continental Ebola response plan on June 5, aiming to raise US$518 million to support African countries' response capacity. [5]
  • WHO issued its first-ever comprehensive clinical management guidelines for all filovirus diseases — including all Ebola types and Marburg — on June 17, 2026. [2]
  • On July 2, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, detecting BDBV genetic material in blood samples. [6]
  • The PARTNERS clinical trial opened patient enrollment in DRC on July 2, 2026, representing the first organized effort to identify effective treatments specifically for Bundibugyo virus disease. [3]
  • CDC enhanced Ebola entry screening at Washington Dulles on May 21 and expanded it to Atlanta on May 23 to intercept travelers from affected regions. [7] [8]
  • A CDC statement dated July 10, 2026 confirmed continued active monitoring of the DRC and Uganda situation. [9]

CYCLOSPORA — TACO BELL ICEBERG LETTUCE, MULTI-STATE

  • Shredded iceberg lettuce served at Taco Bell locations is the confirmed source of a Cyclospora outbreak in five states, with 1,644 people sick as of July 17, 2026. [10]
  • The outbreak expanded to four additional states by July 24, 2026, per CDC update; consumers in affected states are urged to avoid Taco Bell shredded iceberg lettuce.

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius was published July 2, 2026, following the original notification of severe acute respiratory illness aboard the vessel on May 2.
  • A CDC transcript from June 24, 2026 confirmed ongoing U.S. government monitoring of the hantavirus response; CDC previously stated the risk to the general American public remains extremely low.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State, India confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district in an adult male who developed neurological symptoms on May 30 and was hospitalized June 10.
  • An earlier NiV case was also confirmed in Bangladesh's Rajshahi Division in February 2026, with fever and neurological symptoms onset January 21.

WEST NILE VIRUS — UNITED STATES

  • CDC on July 1, 2026 warned of an early, record-case West Nile virus season in the U.S., urging mosquito bite prevention especially over the July 4th holiday weekend.

E. COLI — FROZEN BLUEBERRIES

  • CDC issued an alert on July 7, 2026 warning of an E. coli outbreak linked to recalled frozen blueberries; consumers are advised not to eat recalled product.

YELLOW FEVER — GLOBAL

  • WHO reported that from January 1 to May 26, 2026, six countries reported 79 human yellow fever infections, following elevated transmission activity in the Americas in 2025 that carried into 2026.

MPOX — RECOMBINANT STRAIN

  • WHO documented two cases of a recombinant monkeypox virus (MPXV) strain comprising genomic elements of both clade Ib and clade IIb as of February 2026, flagging recombination as a known but monitored natural process.

🧬 LONGEVITY & AGING

DEMENTIA PREVENTION — WHO UPDATED GUIDELINES

  • WHO released updated guidelines July 15, 2026 estimating that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course.
  • A Lancet Healthy Longevity commentary urges clinicians to prepare for a coming "dementia prevention era," emphasizing that real-world implementation strategies must be adapted to diverse populations.

DELIRIUM AS A BRIDGE TO DEMENTIA

  • Two linked Lancet Healthy Longevity papers propose that delirium caused by severe infection may be a key missing mechanistic link between acute illness and subsequent dementia development in older adults.

NAD+ AND SENESCENT BONE METABOLISM

  • A Europe PMC study (Jiang et al., Bioactive Materials) describes a hierarchical scaffold designed to restore NAD+ homeostasis and redox balance in aged bone tissue by modulating senescent cell metabolism, offering a potential strategy for bone repair in elderly patients.

TELOMERE REPAIR AND NUCLEAR AGING

  • Salmina et al. (Nucleus, 2026) examined how telomeric DNA repair and misrepair occur in dynamic interaction with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, illuminating stress-response pathways relevant to cellular aging.

TAU, EMERIN, AND NEURONAL AGING

  • Sohn et al. (Nucleus, 2026) found that tau-induced cytoskeletal remodeling in neurons involves elevation of emerin, a mechanically sensitive nuclear envelope protein, linking nuclear mechanotransduction to neurodegeneration pathways associated with aging.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • Wang et al. (Annals of Medicine, 2026) showed that recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway, a potential skin longevity application.

HIGH-DOSE INFLUENZA VACCINES IN OLDER ADULTS

  • A Lancet Healthy Longevity meta-analysis (Zhao et al., 2026) found that high-dose influenza vaccines produce better hospitalization and mortality outcomes compared to standard-dose vaccines in older adults, though gaps in access and evidence remain.

P16-INK4A SENESCENCE MARKER VALIDATION

  • Pipella and Thompson (Islets, 2026) highlight that antibody validation is critical when detecting the senescence marker p16-INK4A by immunohistochemistry in pancreatic tissue, cautioning that poorly validated antibodies can produce misleading aging research results.

💊 NEW CURES & APPROVALS

RUXOLITINIB (JAKAFI) — INCYTE CORP

  • Incyte Corp received an FDA supplemental approval (SUPPL AP) for Jakafi (ruxolitinib phosphate, NDA202192), a JAK1/JAK2 inhibitor used in myelofibrosis and polycythemia vera; this action expands its existing label.

MOMELOTINIB (OJJAARA) — GLAXOSMITHKLINE

  • GlaxoSmithKline received a supplemental FDA approval for Ojjaara (momelotinib dihydrochloride, NDA216873), a JAK1/JAK2/ACVR1 inhibitor indicated for myelofibrosis with anemia.

LEUPROLIDE MESYLATE (CAMCEVI ETM) — ACCORD

  • Accord received a supplemental FDA approval for Camcevi ETM (leuprolide mesylate, NDA219745), a GnRH agonist indicated for advanced prostate cancer.

LENALIDOMIDE (REVLIMID) — BRISTOL MYERS SQUIBB

  • Bristol Myers Squibb received a supplemental FDA approval for Revlimid (lenalidomide, NDA021880), an immunomodulatory agent used in multiple myeloma and certain lymphomas.

PITOLISANT HYDROCHLORIDE — NOVITIUM PHARMA

  • Novitium Pharma received an original FDA approval (ORIG AP) for a generic pitolisant hydrochloride (ANDA218495), a histamine H3 receptor antagonist/inverse agonist used to treat excessive daytime sleepiness in narcolepsy.

CANAGLIFLOZIN — TEVA PHARMACEUTICALS USA

  • Teva Pharmaceuticals received an original tentative FDA approval (ORIG TA) for generic canagliflozin (ANDA210451), an SGLT2 inhibitor used in type 2 diabetes management and with cardiovascular and renal protective indications.

TOLVAPTAN — TEVA PHARMACEUTICALS INC

  • Teva Pharmaceuticals received an original FDA approval for generic tolvaptan (ANDA216933), a vasopressin V2 receptor antagonist used for hyponatremia and autosomal dominant polycystic kidney disease.

FLUVOXAMINE MALEATE — ZYDUS PHARMACEUTICALS

  • Zydus Pharmaceuticals received an original FDA approval for generic fluvoxamine maleate (ANDA220447), a selective serotonin reuptake inhibitor (SSRI) indicated for obsessive-compulsive disorder.

🧪 CLINICAL TRIALS

PARKINSON'S DISEASE — ADENOSINE A2A RECEPTOR BLOCKER VG081821AC

  • A Phase IIb trial (NCT07725562) is evaluating the efficacy and safety of oral VG081821AC tablets in patients with early- to mid-stage Parkinson's disease; the drug blocks the adenosine A2A receptor in the brain to improve motor function without classic dopaminergic side effects.

BUNDIBUGYO VIRUS DISEASE TREATMENTS — PARTNERS TRIAL

  • The PARTNERS clinical trial opened enrollment on July 2, 2026 in DRC, representing the first organized effort to identify effective treatments for Ebola Bundibugyo virus disease; WHO convened experts in May 2026 to assess candidate vaccines and therapeutics for BDBV. [3]

MICROPLASTIC AND PFAS REDUCTION — DFPP

  • Trial NCT07658443 is evaluating whether clinically prescribed double-filtration plasmapheresis (DFPP) reduces circulating microplastic, nanoplastic, and PFAS concentrations in peripheral blood in 20 participants; this is a prospective, within-subject paired biomarker study.

PRECISION LAB RESULT COMMUNICATION FOR OLDER ADULTS

  • Trial NCT07391904 is testing a personalized EHR-based lab result communication tool designed specifically for adults aged 65 and older and their providers, replacing standard uniform reporting with patient-specific contextualization.

ANTIRETROVIRAL DRUGS AND METABOLIC AGING — HIV INSTI STUDY

  • Trial NCT05652478 (Phase 2, randomized) is investigating the early metabolic effects of integrase strand transfer inhibitors (INSTIs), a class of HIV drugs associated with weight gain, in healthy volunteers to understand mechanisms that may accelerate cardiometabolic aging.

📢 PUBLIC HEALTH

WHO DROWNING PREVENTION PACKAGE LAUNCHED

  • WHO launched a new technical package on July 23, 2026 outlining seven proven government and community strategies to reduce drowning deaths ahead of World Drowning Prevention Day on July 25.

CANCER CASES PROJECTED TO NEARLY DOUBLE BY 2050 — WHO

  • WHO reported on July 8, 2026 that global cancer cases could nearly double by 2050, with 20.6 million new cases and close to 10 million deaths occurring annually now; the report calls for urgent preventive and early-detection action.

GLOBAL CHILDHOOD IMMUNIZATION — 2025 COVERAGE DATA

  • WHO and UNICEF data released July 15, 2026 show 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose in 2025, with 85% completing the full three-dose series, though conflict and hesitancy continue to impede progress.

MEASLES — BANGLADESH NATIONWIDE SURGE

  • Bangladesh notified WHO in April 2026 of 19,161 suspected measles cases affecting 58 of 64 districts across all eight divisions, with 2,897 laboratory-confirmed cases, representing a serious nationwide resurgence.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO on March 21, 2026 of a confirmed H9N2 avian influenza case in an adult male returning from Senegal; next-generation sequencing confirmed the subtype; the individual had travel-linked exposure.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of preventable blindness.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES 1 MILLION

  • CDC's Traveler-Based Genomic Surveillance biosurveillance program surpassed one million voluntary air travel participants as of January 2026, strengthening early detection of novel pathogen introductions.

BIOMED PULSE is an informational briefing only and does not constitute medical advice. All data sourced from WHO, CDC, openFDA, ClinicalTrials.gov, and Europe PMC/PubMed as indicated.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  3. Patient enrolment begins in a scientific trial to identify the… — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
  10. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260726-02-v39 · 2026-07-26 02:01 UTC · pulse.uzylab.com

Read next